[go: up one dir, main page]

MX2018011854A - Neurotoxina botulinica diseñada. - Google Patents

Neurotoxina botulinica diseñada.

Info

Publication number
MX2018011854A
MX2018011854A MX2018011854A MX2018011854A MX2018011854A MX 2018011854 A MX2018011854 A MX 2018011854A MX 2018011854 A MX2018011854 A MX 2018011854A MX 2018011854 A MX2018011854 A MX 2018011854A MX 2018011854 A MX2018011854 A MX 2018011854A
Authority
MX
Mexico
Prior art keywords
botulinum neurotoxin
substitution mutations
receptor binding
serotype
mutations
Prior art date
Application number
MX2018011854A
Other languages
English (en)
Inventor
Pål Erik Gustav Stenmark
Ronnie Per-Arne Berntsson
Min Dong
Lisheng Peng
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2018011854A publication Critical patent/MX2018011854A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se describen en la presente polipéptidos de neurotoxina botulínica (BoNT) con un dominio de enlace de receptor modificado del serotipo B de Clostridial botulinum (B-HC), que comprenden una o más mutaciones de sustitución correspondientes a las mutaciones de sustitución en el serotipo B, cepa 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; SI 20 IV; o combinaciones de las mismas. Las mutaciones de combinación específica incluyen E1191M y S1199L, E1191M y S1199Y, E1191M y S1199F, E1191Q y S1199L, E1191Q y S1199Y, ó E1191Q y S1199F. También se describen otras mutaciones de sustitución. También se describen dominios de enlace de receptor modificados aislados, moléculas quiméricas, composiciones farmacéuticas y métodos para utilizar los mismos.
MX2018011854A 2012-05-30 2014-11-26 Neurotoxina botulinica diseñada. MX2018011854A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653214P 2012-05-30 2012-05-30

Publications (1)

Publication Number Publication Date
MX2018011854A true MX2018011854A (es) 2020-09-02

Family

ID=48050254

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014014540A MX359480B (es) 2012-05-30 2013-03-13 Neurotoxina botulínica diseñada.
MX2018011854A MX2018011854A (es) 2012-05-30 2014-11-26 Neurotoxina botulinica diseñada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014014540A MX359480B (es) 2012-05-30 2013-03-13 Neurotoxina botulínica diseñada.

Country Status (22)

Country Link
US (3) US9598685B2 (es)
EP (2) EP2854840B1 (es)
JP (3) JP6336970B2 (es)
KR (1) KR102060355B1 (es)
CN (2) CN104736166B (es)
AU (2) AU2013267957B2 (es)
BR (1) BR112014029585A2 (es)
CA (3) CA3170993A1 (es)
DK (2) DK2854840T3 (es)
EA (1) EA029275B1 (es)
ES (2) ES2661033T3 (es)
HU (2) HUE037310T2 (es)
IL (1) IL235934B (es)
MX (2) MX359480B (es)
NZ (1) NZ702310A (es)
PL (2) PL3372239T3 (es)
PT (2) PT3372239T (es)
SG (2) SG10201606666XA (es)
TR (1) TR201802754T4 (es)
UA (1) UA116985C2 (es)
WO (1) WO2013180799A1 (es)
ZA (1) ZA201408757B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2854840T3 (en) 2012-05-30 2018-03-05 Harvard College MANIPULATED BOTULINUM NEUROTOXIN
US10087432B2 (en) * 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP3270951B1 (en) * 2015-03-16 2020-09-09 California Institute of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
RU2746736C2 (ru) * 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EA201892643A1 (ru) * 2016-05-16 2019-06-28 Президент Энд Феллоуз Оф Гарвард Колледж Способ очистки и активации ботулинического нейротоксина
SG10201912099TA (en) 2016-06-08 2020-02-27 Childrens Medical Center Engineered botulinum neurotoxins
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EA201990229A1 (ru) * 2016-07-08 2019-06-28 Пол Стенмарк Новый ботулинический нейротоксин и его производные
WO2018039506A1 (en) * 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018236873A1 (en) 2017-06-19 2018-12-27 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
JP2021500871A (ja) 2017-09-29 2021-01-14 ザ チルドレンズ メディカル センター コーポレーション ニューロトキシン様トキシンおよびそれらの使用
RU2020123346A (ru) 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для лечения расстройств, связанных с фиброзом
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
JP2021517825A (ja) * 2018-01-30 2021-07-29 チルドレンズ メディカル センター コーポレーションＣｈｉｌｄｒｅｎ’Ｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｂａｃｉｌｌｕｓ系を用いたボツリヌスニューロトキシンの生産
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
CN115297887A (zh) 2020-03-16 2022-11-04 益普生生物制药有限公司 用于治疗肢体痉挛的经修饰的肉毒神经毒素
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
US20240016904A1 (en) * 2020-11-25 2024-01-18 Vetmed Therapeutics, Inc. Methods of treating superficial digital flexor tendon injuries, deep and superficial muscle/tendon contracture, navicular syndrome, and suspensory ligament inflammation and injuries in quadruped animals
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
US20250066755A1 (en) 2021-03-30 2025-02-27 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
KR102547393B1 (ko) 2021-04-19 2023-06-23 엠브릭스 주식회사 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
JP2024534384A (ja) 2021-09-16 2024-09-20 イプセン バイオファーム リミテッド 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
CA3228712A1 (en) 2021-09-23 2023-03-30 Nicolae GRIGORE Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
AU2022392458A1 (en) 2021-11-22 2024-05-02 Ipsen Biopharm Limited Treatment of pain
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
CN119823215A (zh) * 2023-10-13 2025-04-15 北京博特维克生物技术有限公司 高效快速重组表达神经毒素蛋白的多肽及其方法
WO2025093844A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
CN118388606B (zh) * 2024-04-25 2025-09-23 武汉大学 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用
KR102790255B1 (ko) * 2025-01-23 2025-04-07 엠브릭스 주식회사 재조합 보툴리눔 독소 및 이를 함유하는 약학 조성물
CN120775067A (zh) * 2025-07-07 2025-10-14 西北农林科技大学 一种毒性增强型神经毒素重组蛋白

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU2431995A (en) 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
EP0760681B1 (en) 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
CA2296765A1 (en) * 1996-08-28 1998-03-05 Ophidian Pharmaceuticals, Inc. Soluble recombinant botulinum toxin proteins
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
KR100668570B1 (ko) 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8586081B2 (en) 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
US8445650B2 (en) 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
AU2009286973B2 (en) 2008-08-29 2014-06-12 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
WO2010056922A2 (en) 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
CN102481351B (zh) * 2009-04-14 2015-05-13 Mcw研究基金会股份有限公司 工程改造的肉毒杆菌神经毒素
US8440204B2 (en) 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
DK2854840T3 (en) 2012-05-30 2018-03-05 Harvard College MANIPULATED BOTULINUM NEUROTOXIN
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
SG10201912099TA (en) 2016-06-08 2020-02-27 Childrens Medical Center Engineered botulinum neurotoxins
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
WO2013180799A1 (en) 2013-12-05
MX2014014540A (es) 2015-02-24
CA2874587C (en) 2022-11-08
EP3372239B1 (en) 2020-11-11
ES2661033T3 (es) 2018-03-27
CA3170993A1 (en) 2013-12-05
DK2854840T3 (en) 2018-03-05
US20170226496A1 (en) 2017-08-10
JP6336970B2 (ja) 2018-06-06
SG10201606666XA (en) 2016-09-29
TR201802754T4 (tr) 2018-03-21
SG11201407784UA (en) 2014-12-30
ES2847241T3 (es) 2021-08-02
CN104736166B (zh) 2018-02-16
AU2018200409A1 (en) 2018-03-01
PT3372239T (pt) 2021-02-02
HUE037310T2 (hu) 2018-08-28
US9598685B2 (en) 2017-03-21
AU2013267957B2 (en) 2017-10-19
CA3248592A1 (en) 2025-11-29
IL235934B (en) 2020-04-30
JP6839239B2 (ja) 2021-03-03
US10190110B2 (en) 2019-01-29
EP3372239A1 (en) 2018-09-12
HUE053147T2 (hu) 2021-06-28
US20190256834A1 (en) 2019-08-22
PT2854840T (pt) 2018-03-02
EP2854840B1 (en) 2018-01-17
JP2017212975A (ja) 2017-12-07
ZA201408757B (en) 2018-05-30
KR102060355B1 (ko) 2019-12-31
JP2019216735A (ja) 2019-12-26
DK3372239T3 (da) 2021-02-01
HK1210692A1 (en) 2016-05-06
PL3372239T3 (pl) 2021-05-04
EA029275B1 (ru) 2018-03-30
AU2018200409B2 (en) 2019-10-10
IL235934A0 (en) 2015-01-29
KR20150029656A (ko) 2015-03-18
CN104736166A (zh) 2015-06-24
MX359480B (es) 2018-09-28
CA2874587A1 (en) 2013-12-05
CN108178801B (zh) 2022-05-03
PL2854840T3 (pl) 2018-07-31
EA201492203A1 (ru) 2015-05-29
EP2854840A1 (en) 2015-04-08
NZ702310A (en) 2016-08-26
US20150166972A1 (en) 2015-06-18
UA116985C2 (uk) 2018-06-11
BR112014029585A2 (pt) 2017-07-25
US10844362B2 (en) 2020-11-24
WO2013180799A9 (en) 2014-12-24
AU2013267957A1 (en) 2014-12-18
JP2015519362A (ja) 2015-07-09
CN108178801A (zh) 2018-06-19
JP6574218B2 (ja) 2019-09-11

Similar Documents

Publication Publication Date Title
MX2018011854A (es) Neurotoxina botulinica diseñada.
EA201892784A1 (ru) Сконструированные ботулинические нейротоксины
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
NZ749810A (en) A novel botulinum neurotoxin and its derivatives
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112015027321A8 (pt) Compostos e composições para modular a expressão de apolipoproteína(a) e seus usos
ZA201803366B (en) Antibody molecules to april and uses thereof
MX380651B (es) Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
BR112018000601A2 (pt) moléculas de anticorpo que se ligam ao cd22
BR112018008454A2 (pt) composição detergente que compreende variantes de amilase e protease
ECSP12011835A (es) Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO6280406A2 (es) Polipeptidos anti-microbianos para uso en el tratamiento de transtornos microbianos
UY33588A (es) Moleculas de union a vegf
AR078516A1 (es) Moleculas de union a dll-4 (ligando 4 de tipo delta)
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
EP3845241A8 (en) Long lasting effect of new botulinum toxin formulations
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
BR112014001834A2 (pt) biocontrole de nematoides
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
CR20140342A (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos hepáticos
AR085919A1 (es) Moleculas de union bioespecificas que se unen a ligando 4 de tipo delta (dii4) y angiopoyetina 2 (ang2)
BR112015024758A2 (pt) proteínas de fusão de ligação à cartilagem